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Abstract 
The synthesis of poly[N,N-bis(3-aminopropyl)glycine] (PAPGly) dendrons Gd-based contrast agents (GdCAs) via an 
orthogonal protection of the different functional groups and an activation/coupling strategy wherein a specific 
number of synthetic steps adds a generation to the existing dendron have been described. The aim of this protocol is 
to build up two different generations of dendrons (G-0 or dendron’s core, and G-1) with peripheral NH2-groups to 
conjugate a 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A) derivative and after to chelate with Gd3+ 
paramagnetic ions. These complexes, which have a well-defined molecular weight, are of relevance to MRI as an 
attempt to gain higher 1H relaxivity by slowing down the rotation of molecule compared to monomeric Gd(III) 
complexes used as contrast agents and to increase the number of paramagnetic centers present in one molecular 
structure. From the study of their water 1H longitudinal relaxation rate at different magnetic fields (NMRD, 
Nuclear Magnetic Relaxation Dispersion) and by evaluating the variable temperature 17O NMR data we 
determined the parameters characterizing the water exchange rate and the rotational correlation time of each 
complex, both affecting 1H relaxivity. 
Furthermore, these two novel PAPGly GdCAs were objects of i) an in-vivo study to determine their biodistributions 
in healthy C57 mice at several time points, and ii) of the Dynamic Contrast-Enhanced MRI (DCE-MRI) approach 
to assess their contrast efficiency measured in the tumour region of C57BL/6 mice transplanted subcutaneously 
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with B16-F10 melanoma cells. The aim of the comparison of these two dendrons GdCAs, having different 
molecular weights (MW), is to understand how the relationship between MW and relaxivity may influence the 
contrast enhancement capabilities in vivo at low magnetic field (1 T). Significant contrast enhancement was 
observed in several organs (vessel, spleen and liver), already at 5 min post-injection, for the investigated CAs. 
Moreover, these CAs induced a marked contrast enhancement in the tumour region, thanks to the enhanced 
permeability retention effect of those macromolecular structures. 
 
 
Introduction 
Magnetic resonance imaging (MRI) has become a powerful non-invasive diagnostic imaging modality 
that provides high-quality anatomic images and other physiologic data. Its advantages include a high 
spatial resolution, a non-ionizing radiation source, and the ability to extract, simultaneously, 
physiological and anatomical information of soft tissue (1, 2). However, a major limitation of MRI 
remains its inherent low sensitivity. To increase the sensitivity of MRI, scientists have developed non-
toxic contrast agents (CAs) over the last few decades, which are administered to the patient to enhance 
image contrast between normal and diseased tissue or to indicate the status of organ function or blood 
flow (3,4). The development of new MRI contrast agents offers intriguing challenges for investigators 
in the chemical, physical, and biological sciences, including the design and synthesis of stable, non-
toxic, and tissue-specific metal complexes and the understanding of their effect on relaxation behaviour 
in solution and in tissues. These biocompatible contrast agents alter the longitudinal (T1) and transverse 
(T2) relaxation times of the surrounding water protons, therefore enhancing image contrast in tissues 
of interest. For this reason, MRI CAs are generally categorized as T1 and T2 CAs based on their magnetic 
properties and relaxation mechanisms. Gadolinium chelates are effective for increasing T1 relaxation 
rate (1/T1) and commonly used as T1 CAs, generating a positive image contrast (5). Superparamagnetic 
iron oxide nanoparticles are more effective for increasing T2 relaxation rate (1/T2) and commonly used 
as T2 CAs, producing negative image contrast (6). 
Clinical MRI contrast agents are low molecular weight complexes that have transient tissue retention 
due to their short half-life. These agents are nonspecific, extravagate rapidly from blood circulation and 
distribute throughout the extracellular space of normal and diseased tissues. Their unfavourable 
pharmacokinetic profile makes these agents unsuitable for MR angiography and for the early detection 
of cancer tissue. In addition, these low molecular weight complexes show some restrictions to reach the 
ideal (or maximum attainable) relaxivity (7). 
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In fact, the rapid extravasation of low MW contrast agents causes a fast decrease in their concentration 
in the bloodstream after administration. As a consequence, this not only result in a lower signal 
enhancement in the normal blood vessel, but also in a higher background signal from the surrounding 
tissue. An increase in the background signal may reduce the spatial resolution such that blood vessels 
can no longer be discriminated from their surroundings. Contrary to low MW contrast agents, high 
MW contrast agents remain in high concentrations in the bloodstream. Due to the fact that high MW 
contrast agents show little extravasation and long intravascular retention, they are commonly referred 
to as blood pool agents, while low MW contrast agents are referred to as extravascular agents (7). First 
attempts to improve r1, hence, contrast efficiency, was pursued by non-covalent binding of low MW 
contrast agents to the human serum albumin. 
Secondly, low MW contrast agents rapidly diffuse from the bloodstream into the interstitial space, even 
in the case of healthy vessels. This relatively high permeability prevents their effective use in 
differentiating between benign lesions (normal vessels) and malignant tumours (hyperpermeable 
vessels) with contrast-enhanced MR imaging. On the other hand a better differentiation between these 
two types of vessels is possible with high MW contrast agents (8). 
Thirdly, low MW contrast agents, such as Gd(III) complexes of 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA), contain typically one Gd3+ ion per molecule. Consequently, the relatively low 
signal enhancing effect (or longitudinal relaxivity r1, s-1 mM-1) requires that high concentrations (i.e. high 
doses) of MRI contrast agent must be administered to eventually obtain sufficient contrast between the 
blood vessel and its surrounding tissue. A straightforward approach to increase the loading of Gd3+ per 
molecule is to attach multiple Gd(III) chelates to a macromolecular scaffold. An additional advantage 
of (covalently) attaching multiple Gd(III)-based complexes to high MW structures is the strong increase 
in r1 per Gd3+ as a result of the strong reduction in the molecular tumbling rate of the Gd(III) complex 
(7, 9).  
Likewise of inulin-Gd-DO3A complexes (10), several natural and synthetic polymers, such as starch 
polysaccharide (11), dextran (12) or polylysine (13), have been modified and conjugated to contrast 
agents, and showed good efficiency in imaging. However, their use was limited because of synthetic and 
purification difficulties (polydispersity), low level of characterisation and non-reproducibility of the 
final chemical entities.  
Dendrimers can offer several advantages as contrast agents compared to the traditional linear polymers. 
The dendritic architecture has a highly branched, three dimensional nanoscale structure with very low 
polydispersity, high functionality and inherent rigidity higher than the macromolecular linear polymers. 
Actually dendrimer-based contrast agents provide numerous benefits over low-molecular-weight 
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gadolinium chelates for MRI, including enhanced r1 relaxivity (14,15) due to slow rotational dynamics, 
tunable pharmacokinetics that can be adapted for blood pool (16,17), liver, kidney, and lymphatic 
imaging, the ability to be a drug carrier, and flexibility for labeling due to their inherent multivalency 
(11, 18).  
An important aspect for the in vivo application of these MRI contrast agents is that the relaxivity of 
Gd(III) complexes is field-dependent and, in the case of the paramagnetic macromolecular system, it 
shows a maximum efficiency at ca. 1 T (19, 20). The theory of paramagnetic relaxation describes well 
this experimental observation, since contrast agents with optimized water exchange rate (τM) show 
highest overall relaxivity at around 1 T, which is mainly controlled by the long rotational correlation 
time (τR) characteristic of the paramagnetic macromolecules (21). On the other hand, high fields 
provide an overall increase of the signal intensity (SI) that allows the rapid acquisition of highly resolved 
images.  
The first dendrimeric MRI contrast agents were reported by Adam et al. (22) and Wiener et al. (23). 
Since then, many dendrimeric MRI CA have been reported using various dendrimers, including 
poly(amidoamine) (PAMAM) (25), poly(propylene imine) (PPI) (25, 26) and poly-L-lysine (PLL) (27). 
Dendrimeric Gd(III) complexes have showed higher relaxivity due to the more rigid structure than their 
linear polymeric counterparts (7, 28-30). Langereis et al. (25) reported that a Gd-DTPA conjugated to 
poly(propylene imine) dendrimer (the fifth generation G-5, Mw = 51 kDa) had r1 relaxivity as high as 
19.7 s-1 mM-1 per Gd(III) (1.5 T, 20 °C), which was 4.7 times that of Gd-DTPA. Dendrimer-based Gd(III) 
chelates were effective for contrast enhanced MRI of the kidneys, vasculature, liver, or tumour (31, 32). 
Here we report a “convergent synthesis” of poly[N,N-bis(3-aminopropyl)glycine] (PAPGly), as new 
dendrons Gd-based contrast agents. We describe the parameters governing the relaxivity of these new 
materials comparing them with those reported previously. We report also an in-vivo study in healthy 
mice and in mice with transplanted subcutaneously melanoma cells of those new PAPGly dendrons 
Gd-based contrast agents, having generation G-0 and G-1, in order to determine and compare their 
biodistributions and contrast efficiency by Dynamic Contrast-Enhanced MRI (DCE-MRI) at low 
magnetic field (1 T). 
 
Results and Discussion    
Synthesis of poly[N,N-bis(3-aminopropyl)glycine] dendrons Gd-based contrast agents  
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The following approach described for the synthesis of these poly-amino-propyl-glycine (PAPGly) 
dendrons (Fig. 1) was based on the suitably convergent method of multibranched dendrimers synthesis 
mentioned above. We synthesised two different generations of dendrons G-0 (or dendron’s core) and 
G-1, via an orthogonal protection of the different functional groups and an activation/coupling 
strategy, wherein each synthetic step adds a generation to the existing dendron. 
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Figure 1: Chemical structures of ligand L1 and the PAPGly drendrons with two different generations (G-0, G-1).  
 
In the first step (Scheme 1), the primary amine functions in the commercially available polyamine 3, 3'-
diaminodipropylamine 1 were protected using t-Boc groups producing compound 2 in 75% yield. The 
t-Boc group was used since it is stable toward hydrogenation and basic reaction conditions. In the next 
step, benzyl bromo acetate was used as alkylation reagent in the presence of DIEA using DMF as solvent. 
Purification of 3 by silica gel column chromatography using EtOAc/Heptane (70:30) as eluent 
produced white crystals in 90% yield. Removal of the benzyl protecting group of compound 3 was 
accomplished by hydrogenation at 60 psi using MeOH as solvent giving the deprotected polyamine 
derivative 4. Subsequently the Boc group was removed by using TFA in DCM, to give the dendron G-
0.  
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The ligand L1 (Fig. 1) was prepared via the synthetic route reported recently (33). The intermediate 
isocyanate-activated DO3A derivative (DO3A-NCSPP) of the chelate L1, freshly prepared, was used to 
conjugate with the dendron G-0 in order to obtain the product G-0(L1)2. 
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Scheme 1: Synthesis of dendron generation G-0 (or core) and its gadolinium complex G-0(GdL1)2: (i) tert-butyl phenyl 
carbonate, DMF, room temperature (rt); (ii) benzylbromo acetate, DIPEA, DMF; (iii) Pd/C 10 %, MeOH, H2 at 60 psi; (iv) 
CF3COOH/CH2Cl2 50%, rt; (v) CSCl2, CCl4/water, rt; (vi) GdCl3·6H2O, pH 6.5-7.0. 
The generation one of the dendron (G-1) was efficiently synthesised in solution (CH3CN) through the 
activation of the intermediate 5 (2.8 eq.) by using the reagent HATU, 1-[bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, to generate an active ester from the 
carboxylic acid, and subsequent N-acylation with the primary amines of intermediate 4, in the presence 
of DIPEA as organic base (Scheme 2). This typical peptide coupling leads the product 6, which was 
purified by flash chromatography on silica gel using DCM/CH3OH as mobile phase, obtaining a white 
crystal compound after evaporation of the solvent. The orthogonal deprotection of the carboxylic acid 
and the primary amine groups of compound 6 provide G-1 dendron, by which its conjugation with the 
intermediate DO3A-NCSPP derivative of ligand L1 gives the product G-1(L1)4 (Scheme 2). 
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Scheme 2: Synthesis of dendron generation G-1 and its gadolinium complex G-1(GdL1)4: (i) Pd/C 10 %, MeOH, H2 at 60 
psi; (ii) CF3COOH/CH2Cl2 50%, rt; (iii) CH3CN, HATU, DIPEA; (iv) CSCl2, CCl4/water, rt; (v) GdCl3·6H2O, pH 6.5-
7.0. 
 
The Gd3+ complexes of both dendrons were prepared by adding stoichiometric amount of Gd3+ chloride 
to an aqueous solution of the ligands G-0(L1)2 and G-1(L1)4 (Schemes 1 and 2) while maintaining the 
pH of the solution between 6.5-7.0 by addition of 1 M NaOH aqueous solution. After 3-4 days the 
reaction mixture was stopped, and the excess of free lanthanide of dendron complex G-0 was removed 
by centrifugation as Gd(OH)3 precipitate, which appeared at pH 10 after addition of 1 M NaOH, 
whereas for G-1 complex the free gadolinium was removed by membrane ultra-filtration. The absence 
of free Gd3+ ions was confirmed in both cases by a xylenol orange test. 
 
Evaluation of the relaxivity and its parameters  
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The relaxivity depends on various factors including the external field, the number of coordinated water 
molecules, water exchange rate, rotational diffusion, first and second coordination sphere hydration, 
and the ion to water proton distance (9). DOTA-like chelates, such as the DO3A-p-aminophenyl-
propan-1-one (10), have a single water molecule coordinated to the Gd3+ ion. Parameters such as the 
rate of the water exchange (τM) and the rotational dynamics of the molecule (τR) are most affected when 
attaching contrast agents to a polymer. Ideally for a small organic contrast agent, τM should be at 
maximum 10 ns and τR should be at least higher than 10 ns at a magnetic field of 1.5 T (most commonly 
used in clinical MRI scanners) (36). The results of relaxometric studies by fitting the 17O NMR and 1H 
NMRD data of the G-0(GdL1)2 and G-1(GdL1)4 dendrons complexes (Table 1) indicated an overall 
increase in relaxivity compared to the r1 of the monomeric GdL1 complex previously studied (33) and 
of the commercial Gd-DOTA complex. As expected, the increase is the highest for the dendron agent 
at high generation (G-1) (Fig. 5b), with its relaxivity being 4 times higher than the monomeric 
macrocyclic Gd3+poly(amino carboxylate) complex (Gd-DOTA and GdL1, Table 1). 
In order to determine the water exchange rate, a variable temperature 17O NMR study was performed 
on the dendritic Gd3+-complexes of the two different generations and on the monomeric complex. 
From the Table 1 and the Figure 5a, it appears there is no dramatic difference between the monomer 
and the G-0(GdL1)2 complex, whereas for G-1(GdL1)4 complex we can observe a somewhat longer water 
residence time. This is probably due to a steric constraint around the second coordination sphere of 
the Gd3+-complex which limits the access to the water bulk to be coordinated to the paramagnetic 
centre. The study of 1H NMRD profiles of these complexes, which take into account the second-sphere 
contribution, showed that the number of water molecules in the second-sphere (qss) is zero for the G-
1(GdL1)4 dendron complex comparing to the G-0(GdL1)2, where  qss = 3 (Table 1). This is in line with 
the previous observation. As one of the most important outcomes of this study, we can thus confirm 
that the attachment of the macrocyclic unit to a large dendritic polymer molecule does not dramatically 
influence the kinetics of water exchange on the complex. These results are in line with most of the 
general conclusions reported in literature concerning macrocyclic units attached to the well definite 
dendritic architecture with its higher degree of symmetry and rigidity than the hyperbranched and 
linear polymers macromolecular systems (7, 24, 29, 32).     
This finding allows to predict water exchange rates for Gd(III) complexes attached to 
dendrons/dendrimers by determining this parameter for the monomeric chelate, before the tedious 
synthesis of whole molecule. 
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Figure 5 (a) Temperature dependence of the reduced 17O transverse relaxation rate at 11.75 T; (b) comparison between 1H 
NMRD profiles of GdL1 1.78 mM (spheres), G-0(GdL1)2 1.59 mM (squares), G-1(GdL1)4 0.90 mM (triangles) and Gd-DOTA 
(stars). The lines represent simulation using the best-fit parameters (Table 1). 
 
The most important expectation for the dendritic contrast agents was that the rotational correlation 
time, τR, which limits the proton relaxivity of current contrast agents at imaging fields, would be 
increased. The longer the rotational correlation time, the greater is the potential for a higher relaxivity 
of the agent. In our present study, we address the problem of the paramagnetic enhancement by 
increasing the molecular weight of the contrast agent. As expected for large molecules previously 
reported, and for these systems described in the present work, the values of the τR are higher than those 
found for monomeric Gd3+ complexes (Table 1), which results in an increase of the relaxivity mainly at 
high field where a hump can be observed on the NMRD profile of G-1(GdL1)4 (r1 = 49.6 and 14.4 s-1 
mM-1 for G-1(GdL1)4 and G-0(GdL1)2 respectively, at 20MHz (37 ° C)). 
 
Table 1 Parameters of GdL1, G-0(GdL1)2 and G-1(GdL1)4 obtained from the analysis of 17O NMR and 1H NMRD data 
compared with Gd-DOTA as a reference. 
  
Reference   
(35) 
New Complexes 
 Parameters Gd-DOTA GdL1 G-0(GdL1)2 G-1(GdL1)4 
r1b [mM−1 s−1] 3.5 4.7 7.2 12.4 
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r1c [mM−1 s−1] 3.5 4.7 14.4 49.6 
τV 310(ps) 7 ± 1.0 19.2 ± 1.1 (23.8)a 22.6 ± 2.14 (22)a 47.1 ± 1.92 (6)a 
τM 310(ns) 122 ± 10 331 ± 44 364 ± 22 541 ± 60 
τR310(ps) 53 ± 1.3 93.1 ± 2.2 152 ± 4.87 473 ± 10.9 
τS0310(ps) 404 ± 24 74.8 ± 1.2 72.0 ± 5.43 127 ± 1.63 
qSS    3.15 ± 0.108 - 
τSS(ps)     18.3 ± 2.89 10.5 ± 49.8 
(a) The first values were obtained from the fitting of the proton NMRD profile; the values in 
parentheses were obtained from the fitting of the 17O NMRD data; (b) r1 corresponds to the relaxivity 
per Gd-complex, (c) per molecule, both calculated at 20 MHz and 37 °C. 
 
 
In vivo evaluation of biodistribution and contrast enhancing properties in tumour bearing mice 
Biodistribution of the two investigated molecules was studied in healthy C57 mice at several time points 
following intravenous injection at doses of 0.05 mmol Gd/kg (Fig. 6, left). All the molecules were 
completely cleared from the vascular compartment 24h post their administration. A pronounced 
accumulation within the spleen was observed for all the two compounds, even the day after the 
administration, with similar contrast enhancements values 24h post injection, probably due to the large 
size of these compounds. A different distribution was observed within the liver, with higher contrast 
enhancement values for G1(GdL1)4 in comparison to G-0(GdL1)2. 
Fig. 6 (right) shows the dynamic signal intensity enhancements in the tumour regions of C57BL/6 mice 
transplanted subcutaneously with B16-F10 melanoma cells. Significant contrast enhancement was 
observed, already at 5 min post-injection, for G-1(GdL1)4 and G-0(GdL1)2, of 42%, and 28%, 
respectively. The contrast enhancement slowly reduced thereafter for G-1(GdL1)4, while for G-0(GdL1)2 
remained quite constant along time. Measurements of relative area under the curve (AUC) clearly show 
a higher contrast enhancement inside the tumour region for G-1(GdL1)4 that becomes more evident 30 
min after the injection. 
All the investigated CAs induced a good contrast enhancement in the tumour region, thanks to the 
enhanced permeability retention effect, at the investigated doses of 0.05 mmol Gd/kg (Fig. 7). G-
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0(GdL1)2 showed the lower contrast enhancement and accumulation inside tumour region, despite 
almost no uptake in the liver. This can be explained by the small size of this system that results in faster 
wash-in and wash-out properties, combined with the lowest relaxivity efficiency. Conversely, G-1(GdL1)4 
showed a better contrast enhancement and accumulation within tumour.  
 
 
 
 
 
 
 
 
 
Figure 6: (Left): signal intensities contrast enhancements measured in the heart (top), spleen (middle) and liver (bottom) at 
various time points post-injection (30 min, 1h, 2h, 4h and 24h) of G-1(GdL1)4 and G-0(GdL1)2 at the same dose of 0.05 
mmol Gd/kg. Values are shown as mean ±SD (n=2 mice) for each contrast agent; (Right): time course of MRI signal intensity 
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enhancement (top) and calculated area under the curve (AUC, bottom) in tumour bearing mice after intravenous injection 
of G-0(GdL1)2 (black squares), and G-1(GdL1)4 (red squares) at a dose of 0.05 mmol Gd/kg at several time points post 
injection 10, 20, 30 and 50 min. Values are shown as mean ±SD (n=3 mice) for each contrast agent. 
 
 
 
Figure 7: Representative tumour SI enhancement maps over imposed onto anatomical T2w images upon injection of G-
0(GdL1)2, and G-1(GdL1)4 at a dose of 0.05 mmol Gd/kg. 
 
 
Conclusions 
A convenient methodology has been presented for the synthesis of poly[N,N-bis(3-aminopropyl)glycine] 
(PAPGly) dendrons Gd-based contrast agents for MR imaging. By orthogonal chemistries, a novel 
synthetic methodology has been developed to obtain two generations of PAPGly dendrons conjugated 
with a low molecular weight Gd-DO3A-based complex. The longitudinal (r1) relaxivities of these MRI 
contrast agents increase along with their size, indicating a longer rotational correlation time for the 
high dendron generation. Consequently, very high relaxivities were observed (r1 = 14.4 s-1 mM-1 and 
49.6 s-1 mM-1 for the G-0(GdL1)2 and G-1(GdL1)4 per molecular complex, respectively). These values are 
significantly higher in comparison with parent monomeric GdL1 (r1 = 4.7 s-1 mM-1) complex and with 
the commercial one (Gd-DOTA, r1 = 3.5 s-1 mM-1). Our MRI results support the hypotheses that the 
Gd-based dendrons with high molecular weight, or macromolecular dendrimers Gd-complexes, can 
improve contrast enhancement as a result of its higher relaxivities comparing to the low molecular 
weight contrast agents. Furthermore, high structural and chemical homogeneity of the dendritic 
polymers can differ significantly from linear polymers in their properties. For example, biodistribution 
and pharmacokinetic properties can be tuned more easily by controlling dendrimer size and 
conformation. 
Consequently, when those dendritic contrast agents are applied for DCE-MRI in mice they provide an 
opportunity to noninvasively extract important physiological and pathophysiological information. 
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Experimental Section 
 General methods and materials 
All reagents and chemicals were obtained from commercial sources and used without further 
purification. Solvents were distilled and/or dried prior to use by standard methodology except for 
those, which were reagent grades. Water was demineralized prior to use. Unless stated otherwise, all 
the reactions were carried out under a nitrogen atmosphere and the reaction flasks were pre-dried by 
heat gun under vacuum. The pH values of the samples were measured at ambient temperature using a 
Corning 125 pH meter with a calibrated micro-combination electrode purchased from Aldrich. The 
pH values of the solution were adjusted using aqueous solution 1M NaOH, 1N pyridine or 1N HCl. 
Most of the reactions were monitored by TLC on silica plates detecting the components by UV light 
or by applying the Dragendorff reagent, while other product formations were monitored via analytical 
HPLC (Waters W600, with a quaternary pump gradient module) with an UV detector coupled with a 
Waters Micromass ZQ system (Waters, Belgium). For low molecular weight characterization, ESI-
QTOF-MS were obtained on a Q‐TOF Ultima GLOBAL mass spectrometer (Waters-Micromass, 
Manchester, UK), whereas for high molecular weight products, MALDI spectra were obtained on 
MALDI-TOF spectrometer (Waters-Micromass, Manchester, UK). 
The purification of the compounds was performed on KP-silica and KP-C18 Biotage cartridges over a 
Biotage flash chromatography instrument, Uppsala, Sweden. 1H-NMR, 13C-NMR spectra were recorded 
on either a Bruker Avance-300 MHz or a Bruker Avance II‐500 MHz spectrometer, at 25°C. Chemical 
shifts are given in ppm (δ) values. Data are reported as follows: chemical shift (multiplicity: s = singlet, 
d = doublet, t = triplet, q = quadruplet, m = multiplet, br = broad resonance) J = coupling constant (Hz), 
integration, peak assignment in italic form.  
Signal Intensity Enhancements in different organs were calculated by using ImageJ and drawing ROIs 
encompassing the whole organs. All the DCE-MRI images were analysed using in-house developed 
software in MatLab (MathWorks, Natick, MA). Relative Area Under the Curve (AUC) were calculated 
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by integrating the signal intensity enhancements along the time curve at different time points post Gd-
compounds injections. 
 
 Synthesis of bis-(3-tert-butoxycarbonyl-aminopropyl) amine (2) 
To a solution of the bis-(3-aminopropyl) amine 1 (10 g, 0.0762 moli) in DMF (75 ml) was added tert-
butyl phenyl carbonate (32.63 g, 0.168 moli) (75). The reaction mixture was stirred for 40h at rt. and 
poured into a phosphate buffer (1L; 0.025 M K2HPO4 and 0.025 M NaH2PO4). The pH was adjusted 
to 3 with aq. H2SO4 (2M) and mixture was extracted with CH2Cl2 (2x250 ml). The aq. phase was made 
strongly alkaline with aq. NaOH (9M) and extracted with CH2Cl2 (3x250 ml). The organic phase was 
dried (Na2SO4), filtered and concentrated in vacuo. The residual solvents (DMF and H2O) were 
removed by drying the protected amine at less than 0.1 mmHg at 40 °C, to obtain a white solid 
compound 2 (18.9 g, 75% of yield). ESI MS: m/z 332 [M + H]+; 1H NMR (300 MHz, CDCl3, 25 °C): δ 
1.35 (s, 18 H), 1.58 (4H, q, 2xCH2CH2CH2), 2.06 (2H, br s, 2xCONH), 2.57 (4H, t, 2xNHCH2CH2), 
3.11 (4H, br t, 2xCONHCH2), 5.32 (1H, br s, NHCH2). 13C NMR (300 MHz, CDCl3, 25 °C): δ 28.35, 
29.60, 38.68, 47.16, 77.88, 156.16. 
 
 Synthesis of benzyl N,N-bis {3-[(tert-butoxycarbonyl) amino] propyl} glycinate (3) 
Compound 2 (6.78 g, 0.02 mol) and 10 ml DMF were dissolved in a three-necked flask under stirring. 
The mixture was cooled by using an ice bath followed by addition of benzyl bromo-acetate (4 ml, 0.025 
mol) and DIPEA (3.5 ml, 0.02 mol) over a time period of 30 min. The resulting reaction mixture was 
stirred at 0 °C for additional 30 min, whereupon it was allowed to reach rt. The reaction mixture was 
reacted for additional 4h at rt. Ether (70 ml) was added and the formed white precipitate was collected 
by filtration, while the mother liquid was evaporated to dryness. The produced oil was dissolved in 70 
ml DCM and carefully washed sequentially with 3 x 50 ml water, 2 x 50 ml 1M HCl, and 3 x 50 ml 
water. The organic phase was dried over Na2SO4 followed by evaporation to dryness. The crude product 
was purified by silica gel column chromatography using EtOAc/Heptane (70:30) as eluent, and the 
pure product 3 was obtained in a yield of 90%, 8.63 g. ESI MS: m/z 480 [M + H]+; 1H NMR (300 MHz, 
CDCl3, 25 °C): δ 1.45 [18H, s, 2xC(CH3)3], 1.65 (4H, br s, 2xCH2CH2CH2), 2.62 (4H, br s, 
2xNCH2CH2), 3.18 (4H, br t, 2xCH2CH2NH), 3.37 (2H, br s, COCH2N), 5.17 (2H, s, COCH2Ar), 
5.24 (2H, br s, 2xCONH), 7.37 (5H, br s, ArH5). 13C NMR (300 MHz, CDCl3, 25 °C): δ 27.32, 28.45, 
38.79, 52.11, 55.03, 66.30, 78.82, 128.37, 128.39, 128.59, 135.67, 156.10, 171.33. 
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 Synthesis of N,N-bis{3-[(tert-butoxycarbonyl) amino] propyl} glycine (4) 
Compound 3 (2.1 g, 4.37 mmol), Pd/C 10% (324 mg) and 100 ml MeOH were mixed in a sealed tube, 
whereupon hydrogen pressure of 60 psi was applied. The mixture was reacted 22h at rt. The resulting 
reaction mixture was filtered through a Celite pad and carefully washed with 150 ml MeOH. The 
mother liquid was evaporated to dryness, and white product 4 was obtained in a yield of 1.6 g. ESI MS: 
m/z 390 [M + H]+; 1H NMR (300 MHz, CD3OD, 25 °C): δ 1.45 [18H, s, 2xC(CH3)3], 1.91 (4H, br s, 
2xCH2CH2CH2), 3.17 (4H, br s, 2xNCH2CH2), 3.36 (4H, br t, 2xCH2CH2NH), 3.69 (2H, br s, 
COCH2N). 13C NMR (300 MHz, CD3OD, 25 °C): δ 26.04, 28.84, 38.23, 54.54, 56.78, 80.33, 158.74, 
170.07. 
 
 Synthesis of N,N-bis(3-aminopropyl) glycine (G-0) 
In a round bottom flask, compound 4 (1.0 g, 2.1 mmol) was dissolved in 20 ml of 50% solution of TFA 
in dry DCM, whereupon the mixture was stirred for 24h at rt. The reaction mixture was evaporated to 
dryness under reduced pressure, and the crude product was washed 2 times with ethyl ether (in a sonic 
bath) in order to remove further impurities, to give the compound G-0 (1.358 g, pale-white colour, 
TFA-salt). ESI MS: m/z 280 [M + H]+; 1H NMR (300 MHz, CDCl3, 25 °C): δ 1.69 (4H, q, 
2xCH2CH2CH2), 2.56 (4H, t, 2xNCH2CH2), 2.71 (4H, t, 2xCH2CH2NH2), 3.86 (2H, s, COCH2N). 13C 
NMR (300 MHz, CDCl3, 25 °C): δ 23.94, 38.40, 53.15, 55.02, 69.02, 129.69, 129.71, 129.75, 136.43, 
169.38. 
 
 Synthesis of G-0(L1)2 
Compound G-0 (190 mg, 0.456 mmol) was dissolved in water (25 ml), and the pH was adjusted to 9-
10 with diluted NaOH aqueous solution. DO3A-NCSPP (771 mg, 1.44 mmol) freshly prepared as 
previously reported in chapter 3, was added, and the reaction mixture was stirred at room temperature 
for 48 h. The solution was freeze-dried to get a yellow powder (832 mg). A portion of crude compound 
(100 mg) was purified by using a semi-preparative HPLC condition: RP-C18 column; CH3CN/H2O 
(buffer NH4HCO3, pH=7.5) as mobile phase; gradient 5-30% CH3CN in 30 min with a flow rate 1 
ml/min; to obtain 70 mg of pure pale-yellow compound G-0(L1)2. ESI MS: m/z 1261 [M + H]+; 1H NMR 
(500 MHz, D2O, 25 °C): δ 1.22 (6H, br s, 2xCH3CHCO), 1.97 (4H, br s, CH2CH2CH2), 2.82-3.91 
(54H, 2 br m), 4.81 (2H, br s, 2xCH3CHCO), 7.31 and 7.70 (8H, 2 br d, ArH). 13C NMR (500 MHz, 
D2O, 25 °C): δ 13.10, 23.67, 41.09, 44.07, 45.24, 48.88, 50.89, 51.50, 52.71, 54.87, 55.68, 56.57, 
56.93, 100.00, 123.37, 129.80, 132.21, 142.48, 169.56, 170.35, 170.54, 177.07, 179.97, 203.07. 
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 Synthesis of benzyl N,N-bis(3-aminopropyl) glycinate (5) 
In a round bottom flask, compound 3 (1.1 g, 2.3 mmol) was dissolved in 20 ml of 50% solution of TFA 
in dry DCM, whereupon the mixture was stirred for 24h at rt. The reaction mixture was evaporated to 
dryness under reduced pressure, and the crude product was washed 2 times with ethyl ether (in a sonic 
bath) in order to remove further impurities, to give the compound 5 (1.58 g, pale-white colour, TFA-
salt). ESI MS: m/z 280 [M + H]+; 1H NMR (300 MHz, CDCl3, 25 °C): δ 2.09 (4H, q, 2xCH2CH2CH2), 
3.06 (4H, t, 2xNCH2CH2), 3.21 (4H, t, 2xCH2CH2NH2), 4.06 (2H, s, COCH2N), 5.27 (2H, s, 
COCH2Ar), 7.37 (5H, m, ArH5). 13C NMR (300 MHz, CDCl3, 25 °C): δ 23.94, 38.40, 53.15, 55.02, 
69.02, 129.69, 129.71, 129.75, 136.43, 169.38. 
 
 Synthesis of benzyl N,N-bis{3-[(N,N-bis{3-[(tert-butoxycarbonyl) amino] propyl} glycyl) amino] 
propyl} glycinate (6) 
Into a two-necked round bottom flask, under dry condition (N2), a suspension of compound 4 (1.1 g, 
2.82 mmol), 3 eq. of 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) (1.289 g, 3.39 mmol), and 2.5 eq. of DIPEA (0.365 g, 2.83 mmol) in 
CH3CN HPLC‐grade (70 ml) was stirred for 30 min at RT. Benzyl N,N-bis(3-aminopropyl) glycinate 
(TFA-salt) (5) (0.7 g, 1.13 mmol) was first dissolved in 20 ml of CH3CN with 4 eq. of DIPEA, and added 
dropwise to the reaction mixture over 30 min, [reaction monitored by TLC: CH2Cl2/CH3OH, 9:1, 
with a ninhydrin test]. After 5 h, the reaction was stopped and poured into ethyl acetate (150 ml). The 
organic layer was first washed three times with saturate NaHCO3 solution, and then three times with 
H2O, dried over Na2SO4, and evaporated to dryness to give a pale-white oil compound (1.342 g). A 1.2 
g aliquot of residue product was purified by flash chromatography on silica gel using CH2Cl2/CH3OH 
(9.5:0.5) as mobile phase. After evaporation of the solvent, 812 mg (0.77 mmol, with 75.4 % of total 
yield) of 6 was obtained as a white crystal compound. ESI MS: m/z 1055 [M + H]+; 1H NMR (300 MHz, 
CDCl3, 25 °C): δ 1.42 [36H, s, 4xC(CH3)3], 1.62 (12H, br m, 6xCH2CH2CH2), 2.48 (8H, t, 
4xNCH2CH2), 2.61 (4H, t, 2xNCH2CH2), 3.00 (4H, s, 2xNCH2COONH), 3.13 (8H, q, 
4xCH2CH2NHCOOtert-But), 3.31 (4H, q, 2xCH2CH2NHCO), 3.37 (2H, s, NCH2COOCH2), 5.12 
(2H, s, COCH2Ar), 7.32 (5H, br m, ArH5). 13C NMR (300 MHz, CDCl3, 25 °C): δ 27.63, 27.68, 28.43, 
37.14, 38.53, 51.85, 52.66, 54.91, 58.52, 66.16, 79.03, 100.00, 128.19, 128.27, 128.55, 135.75, 
156.06, 171.31, 171.38. 
 Synthesis of N,N-bis(3-{[N,N-bis(3-aminopropyl)glycyl]amino}propyl)glycine (G-1) 
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The dendron G-1 (156 mg, 0.29 mmol) was obtained after a completely deprotection of compound 6 
(325 mg, 0.31 mmol) by using the same reaction conditions as described for the synthesis of dendron 
G-0. ESI MS: m/z 532 [M + H]+; 1H NMR (300 MHz, CDCl3, 25 °C): δ 1.72 (12H, br m, 
6xCH2CH2CH2), 2.45 (8H, t, 4xNCH2CH2), 2.61 (4H, t, 2xNCH2CH2), 2.83 (8H, q, 4xCH2CH2NH2), 
3.10 (4H, s, 2xNCH2CONH), 3.31 (4H, q, 2xCH2CH2NHCO), 3.73 (2H, s, NCH2COOH). 13C NMR 
(300 MHz, CDCl3, 25 °C): δ 27.08, 30.43, 37.14, 38.53, 51.85, 52.66, 54.91, 58.52, 170.31, 173.38. 
 
 Synthesis of G-1(L1)4 
Compound G-1 (156 mg, 0.29 mmol) was dissolved in water (20 ml), and the pH was adjusted to 9-10 
with diluted NaOH aqueous solution. DO3A-NCSPP (770 mg, 1.43 mmol) freshly prepared as 
previously reported in chapter 3, was added, and the reaction mixture was stirred at room temperature 
for 48 h. The crude product was purified at pH = 7, by ultrafiltration using a membrane with a 
molecular weight cut-off of 1 kDa, to get a pale yellow solid of 0.2 g. MALDI Q-TOF: m/z 2673 [M + 
H]+; 1H NMR (500 MHz, D2O, 25 °C): δ 1.31 (12H, br s, 4xCH3CHN), 1.78-1.95 (12H, br d, 
6xCH2CH2CH2), 2.91-4.00 (122H, br m), 7.42-7.91 (16H, 2br m, 4xArH4). 13C NMR (500 MHz, D2O, 
25 °C): δ 12.95, 13.30, 23.73, 24.05, 36.39, 41.50, 44.12, 45.28, 48.25, 50.91, 51.54, 52.45, 52.86, 
55.45, 56.64, 56.96, 62.50, 72.06, 122.74, 129.74, 131.77, 142.84, 142.97, 169.53, 170.10, 170.50, 
177.78, 179.71, 202.78. 
 
 Preparation of G-0(GdL1)2 and G-1(GdL1)4 dendrons complexes 
The dendrons G-0(GdL1)2 and G-1(GdL1)4 complexes were prepared by a stepwise addition of 
GdCl3·6H2O to a solution of 83 mg (0.066 mmol) and 71 mg (0.026 mmol) of G-0(L1)2 and G-1(L1)4 
respectively, in 5 ml of H2O, maintaining the pH between 6.5 and 7.0 by addition of 1 M NaOH 
aqueous solution. After 4 days the reaction mixture was stopped, and the excess of free lanthanide for 
the G-0(GdL1)2 complex was removed by centrifugation as Gd(OH)3 precipitate, which appeared at pH 
10 after addition of 1 M NaOH, whereas for G-1(GdL1)4 complex the excess of free gadolinium was 
removed by ultra-filtration using a membrane with a cut‐off of 3 kDa. The absence of free Gd3+ ions 
was confirmed by a xylenol orange test, with a final pH of both solutions around 6.5-7.00. The solutions 
were freeze-dried to give a pale-yellow solid for both final complexes: G-0(GdL1)2 95 mg, ESI MS: m/z 
1569 [M + H]+; and 75 mg G-1(GdL1)4, MALDI Q-TOF: m/z 3290 [M + H]+.  
 
 NMRD profiles 
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1/T1 1H NMRD profiles were measured on a Stelar Spinmaster FFC fast field cycling NMR relaxometer 
(Stelar, Mede, Pavia, Italy) over a range of magnetic fields extending from 0.24 mT to 0.7 T and 
corresponding to 1H Larmor frequencies from 0.01 to 30 MHz using 0.6 ml samples in 10 mm o.d. 
tubes. The samples were prepared by dissolution of appropriate amounts of freeze-dried complexes of 
GdL1, G-0(GdL1)2, and G-1(GdL1)4 in Milli-Q water with the pH in the range 6.5-7.0. The exact Gd3+ 
concentration was determined by proton relaxivity measurements at 20 MHz and 37 °C after complete 
hydrolysis in concentrated HNO3. Additional relaxation rates at 20 and 60 MHz were obtained with 
Bruker Minispec mq-20 and mq-60 spectrometers (Bruker, Karlsruhe, Germany), respectively. The 300 
MHz data were obtained on a Bruker Avance-300 high resolution spectrometer. 
Fitting of the 1H NMRD was performed with data processing software that uses different theoretical 
models describing observed nuclear relaxation phenomena (Minuit, CERN Library) (36, 37). The 
theoretical model takes into account the inner-sphere interaction, the outer‐sphere interaction and 
when necessary the second sphere contribution (7). 
 
17O NMR studies 
17O NMR relaxation rate measurements were performed on a Bruker Avance II-500 spectrometer using 
5 mm diameter sample tubes containing 325 μl (pH 6.5-7.00) of G-0(GdL1)2 (25.5 mM) and G-1(GdL1)4  
(15.9 mM) solutions. The temperature was regulated by air or N2 flow controlled by a BVT-3200 unit. 
17O transverse relaxation times of pure water (diamagnetic contribution) were measured using a CPMG 
sequence and a subsequent two-parameter fit of the data points. The 90 and 180° pulse lengths were 
27.5 and 55 μs, respectively. Broadband proton decoupling was applied during the acquisition of all 
17O NMR spectra. 17O T2 of water in complex solution was obtained from line width measurement. 
The data are presented as the reduced transverse relaxation rate 1/T2R=55:55/([Gd complex]⋅q⋅T2P, 
where [Gd complex] is the molar concentration of the complex, q is the number of coordinated water 
molecules and T2P is the paramagnetic transverse relaxation rate obtained after subtraction of the 
diamagnetic contribution from the observed relaxation rate. The number of water molecules in the first 
coordination sphere (q) of the Gd3+ complex G-0(GdL1)2 and G-1(GdL1)4 was determined at 60 °C using 
a Bruker Avance II‐500 spectrometer. The tubes with 5 mm external diameter containing 300 μl of the 
sample with 50 μl of D2O for the lock were used for the measurements. The hydration number q was 
obtained by comparing the 17O NMR chemical shifts of G-0(GdL1)2 and G-1(GdL1)4 with those of Gd-
DOTA and Gd-DTPA (q=1) (7, 38).  
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In vivo studies 
Mice 
6-old-week male C57BL/6 mice (n=3 for each molecule) were inoculated subcutaneously with 3×105 
B16-F10 cell in 100 µL of PBS on both flanks. C57BL/6 mice (Charles River Laboratories Italia S.r.l., 
Calco Italia) were maintained under specific pathogen free conditions in the animal facility of the 
Molecular Biotechnology Center, University of Torino, and treated in accordance with the EU 
guidelines (EU2010/63). All in vivo studies were conducted according to approved procedures of the 
Institutional Animal Care and Use Committee of the University of Torino. Before imaging, mice were 
anaesthetized with a mixture of tiletamine/zolazepam (Zoletil 100; Vibac, Milan, Italy) 20mg/kg and 
xylazine (Rompun; Bayer, Milan, Italy) 5mg/kg and during the acquisition their breath rate was 
monitored throughout in vivo MRI experiments using a respiratory probe. Cannulation of the lateral 
tail vein with a catheter was exploited for intravenous injection of the investigated molecules. 
 
DCE-MRI experiments 
Mice were placed supine in a solenoid Tx/Rx coil with an inner diameter of 3.5 cm. The breath rate 
was monitored throughout in vivo MRI experiments using a respiratory probe (SAII Instruments, Stony 
Brook, NY - USA). MR images were acquired with a 1 Tesla Aspect M2 MRI scanner (Aspect Magnet 
Technologies Ltd., Israel). After the scout image acquisition, a T2-weighted (T2w) anatomical image was 
acquired with a Fast Spin Echo sequence (TR 2500 ms; TE 44ms; number of slices 10; slice thickness 
1.5 mm; FOV 40 mm; matrix 152 × 160; four averages; acquisition time 3 m 20 s). The DCE-MRI 
dynamic protocol consisted of the application of an axial T1-weighted (T1w) 3D spoiled Gradient Echo 
sequence with 3 initial pre-contrast images acquisition that were followed by the injection through the 
catheter of one of the two investigated compounds at the same dose of 0.05 mmolGd/kg. After 
injection, 47 dynamic post-contrast images were acquired with the following parameters: TR = 40 ms; 
TE = 2.1 ms, flip angle = 60°, number of slices = 10, slice thickness = 1.5 mm, FOV = 40 mm, matrix 
= 128 × 128, acquisition time 58 s. 
All the DCE-MRI images were analysed using in-house developed software in MatLab (MathWorks, 
Natick, MA) . 
 
Biodistribution  
6-old-week male C57BL/6 mice (n=2 for each molecule) were administered with the two dendrons Gd-
based contrast agents at a dose of 0.05 mmol Gd/kg. T1w images were acquired before and after i.v. 
injection at several time points: 30 min, 1h, 2h, 4h and 24h. Region of interests (ROIs) were manually 
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placed in several organs (liver, spleen, major vessel) and signal intensity (SI) values were measured and 
contrast enhancement calculated as (SIpost-SIpre)/SIpre. 
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